Introduction Interventions, including commencement of antiretroviral therapy (ARV), have decreased the rate of MTCT to less than 1%. This study looks at women who commenced ARV therapy during pregnancy as this group may be at high risk of MTCT.
Methods A retrospective cohort study of HIV-positive women commencing ARV during pregnancy at a London teaching hospital from January 2004–December 2013.
Results Complete data sets were obtained from 55 HIV-positive pregnant women, (total 59 pregnancies). Median age at diagnosis of HIV was 30.5 (18.2–44.9). 98% contracted HIV through heterosexual contact and one case resulted from MTCT. 26/55 were diagnosed during pregnancy with median gestational age at diagnosis of 16.3 weeks (5.3–37.6). Median gestational age at ARV commencement was 22.8 weeks. Diagnosis during pregnancy was associated with a later start of ARVs (23.4 vs 19.9 weeks, p = 0.02). Viral load at delivery was available in 56 pregnancies from which only 14.3% (8/56) were detectable. 60% (29/48) babies were delivered by Caesarean section (10 emergency and 19 elective). Spontaneous vaginal delivery was achieved in 31% (15/48). Median gestational age at birth was 38 weeks with 21% (10/48) <37 weeks gestation. Average birth weight was 3076g (1100–4096).
Conclusion Antiretroviral therapy commenced during pregnancy, together with a dedicated multidisciplinary team approach, was associated with an extremely low MTCT (1/59). In this small series, no particular drug regimen was associated with prematurity, however this will require further investigation with a larger cohort size.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.